NCT05335811View on ClinicalTrials.gov

First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging

PHASE1RecruitingINTERVENTIONAL

Enrollment

55

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

August 31, 2026

Conditions

Endocrine Neoplasia

Interventions

DRUG

4-[18F]Fluoro-1-Naphthol

By vein (IV)

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER